Transmedics Group Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
(technical difficulty)
have to get here.
Questions & Answers
And on the heels of the panel meeting last spring, we're expecting approval with somewhat of a restricted label, the label you ultimately received is very broad. Can you just talk about the label relative to what you were expecting and walk through areas of upside for OCS utilization based on the broad label versus your expectations?
Sure. Thank you, Cecilia. The label final language was not a surprise for us. We've always stated post panel that we were fairly confident that after the final label has to reflect the patient population that were studied at the -- in the EXPAND trial. So the final label wasn't too much of a surprise for us. We just had to wait for it to be formalized and announced.
The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
